|
Evaluating Brain Tumors
MRI is the procedure of choice for the evaluation of neurologic dysfunction in a patient suspected of having cancer.
MRI and contrast-enhanced CT (computed tomography) scanning have now largely replaced the combination of skull X-ray, electroencephalogram, radionuclide brain scan, and arteriography as the principal tests for the evaluation of patients with suspected brain tumor.
MRI delineates most metastatic and primary tumors of the nervous system. In general, lesions (a wound, injury, or pathological change in body tissue) of the skull base and those in the brainstem, cerebellum, and spinal cord are visualized in greater detail with MRI than with CT, myelographic, or radionuclide images.
In addition to greater sensitivity and delineation of anatomic detail, MRI involves no radiation exposure. Paramagnetic contrast with intravenous gadolinium diethylene-triamine pentaacetic acid (gadolinium DTPA) produces contrast changes in MRI similar to those observed following the use of organic iodides in CT. The combination of paramagnetic agents and higher energy MRI units may provide better separation of tumor from non-tumor tissue and better resolution of the spinal cord and brachial plexus.
Gadolinium DTPA administration occasionally produces hypotension (low blood pressure), nausea or vomiting.
Magnetic resonance angiography (MRA) can also provide detailed information on the status of the intracranial (within the brain) circulation.
(Back to Top)
|